103789-44-2

Basic information

• Product Name: Benzonitrile, 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-
• CAS NO: 103789-44-2
• Molecular Formula: C19H16N2O2
• Molecular Weight: 304.348
• Mol File: 103789-44-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Benzonitrile, 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile, 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-(103789-44-2)
• EPA Substance Registry System: Benzonitrile, 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-(103789-44-2)

Safety Data

• Hazardous Substances Data: 103789-44-2(Hazardous Substances Data)

Upstream product

• 54819-26-0 methyl 3-(benzoylamino)-4-oxovalerate 
• 98-88-4 benzoyl chloride 
• 39741-26-9 N-benzoyl-L-aspartic acid β-methyl ester 
• 1194-02-1 4-fluorobenzonitrile 
• 103788-65-4 (5-methyl-2-phenyloxazol-4-yl)ethanol 
• 103788-64-3 methyl 2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetate 

Downstream Products

• 103788-59-6 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzaldehyde 
• 103789-42-0 5-{4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzylidene}-2,4-thiazolidinedione 

Relevant articles and documents

Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents

In the course of further chemical modification of the novel antidiabetic pioglitazone (AD-4833, U-72, 107), a series of 5-[4-(2- or 4- azolylalkoxy)benzyl- or -benzylidene]-2,4-thiazolidinediones was prepared and evaluated for hypoglycemic and hypolipidemic activities in insulin-resistant, genetically obese, and diabetic KKA(y) mice. Replacement of the 2-pyridyl moiety of pioglitazone by a 2- or 4-oxazolyl or a 2- or 4-thiazolyl moiety greatly enhanced in vivo potency. The corresponding 5-benzylidene-type compounds, in which a methine was used as a linker between the benzene ring and the thiazolidinedione ring, also had potent biological activity. Among the compounds synthesized, 5-[4-[2-(5-methyl-2-phenyl-4- oxazolyl)ethoxy]benzyl]-2,4-thiazolidinedione (18) exhibited the most potent activity, more than 100 times that of pioglitazone. The synthesis and structure-activity relationships for this novel series of derivatives are detailed.